| 726.31 -19.64 (-2.63%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 895.06  |
1-year : | 927 |
| Resists | First : | 766.31 |
Second : | 793.66 |
| Pivot price | 758.73 |
|||
| Supports | First : | 722.07 |
Second : | 600.76 |
| MAs | MA(5) : | 744.1 |
MA(20) : | 762.79 |
| MA(100) : | 687.92 |
MA(250) : | 579.48 |
|
| MACD | MACD : | -4.3 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 9.6 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 800.78 | Low : | 370.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed below the lower bollinger band by 7.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 6.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 751.46 - 755.72 | 755.72 - 760.36 |
| Low: | 710.28 - 714.94 | 714.94 - 720 |
| Close: | 717.52 - 725.62 | 725.62 - 734.42 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Fri, 19 Apr 2024
Eli Lilly and Company (NYSE:LLY) Trading Down 2% - MarketBeat
Fri, 19 Apr 2024
Eli Lilly Shares Show Healthy Rise | FXEmpire - FX Empire
Fri, 19 Apr 2024
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals - Eli Lilly an - Benzinga
Thu, 18 Apr 2024
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Wed, 17 Apr 2024
Top Research Reports for Eli Lilly, Linde & Caterpillar - Yahoo Finance
Wed, 17 Apr 2024
Eli Lilly Stock (NYSE:LLY): Hold Off Until the End of the Month - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 951 (M) |
| Shares Float | 898 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 84.3 (%) |
| Shares Short | 5,420 (K) |
| Shares Short P.Month | 5,420 (K) |
| EPS | 5.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.97 |
| Profit Margin | 15.3 % |
| Operating Margin | 34.1 % |
| Return on Assets (ttm) | 11.8 % |
| Return on Equity (ttm) | 48.4 % |
| Qtrly Rev. Growth | 28.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 35.88 |
| EBITDA (p.s.) | 12.94 |
| Qtrly Earnings Growth | 13 % |
| Operating Cash Flow | 4,240 (M) |
| Levered Free Cash Flow | 237 (M) |
| PE Ratio | 125.44 |
| PEG Ratio | 1.2 |
| Price to Book value | 60.62 |
| Price to Sales | 20.23 |
| Price to Cash Flow | 162.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|